Biopharma - Business Clase

POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update

Ruud Gullit2 years ago027 mins

POINT Biopharma Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of SPLASH trial ongoing, top line data expected mid-2023 Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) inhibitor program, planned for summer 2022 Indianapolis radiopharmaceutical manufacturing facility operational and supplying doses…

POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs

Ruud Gullit2 years ago015 mins

Company’s radiopharmaceutical manufacturing facility now operational, supplying doses for the Phase 3 SPLASH trial – view the facility at manufacturing.pointbiopharma.com Will receive actinium-225 in 2022 from the US Department of Energy Isotope Program to support early-stage pipeline Dosimetry data from the lead-in cohort of the SPLASH trial in mCRPC will be published February 25th in…